SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Cel-Sci (CVM)

CVM RSS Feed
Add CVM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Foxwoods Man, drkazmd65
Search This Board: 
Last Post: 10/17/2017 2:19:16 AM - Followers: 193 - Board type: Free - Posts Today: 1

 Cel-Sci Corporation (CVM)

http://www.cel-sci.com/

https://www.youtube.com/watch?v=auAihG3rtC4

Products In Development

Multikine® (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CANCER - MULTIKINE

Multikine, CEL-SCI's lead investigational immunotherapy, is an immunotherapeutic agent that is being developed as a potential first-line treatment for advanced primary head and neck cancer. If it were to be approved for use following completion of CEL-SCI's clinical development program, Multikine would be a different kind of therapy in the fight against cancer; one that appears to have the potential to work with the body's natural immune system in the fight against tumors.

Multikine may also have the potential to be a first in a new class of cancer immunotherapy drugs. It is the first investigational combination immunotherapy thought to have both passive and active immune properties.  More...

INFECTIOUS DISEASES - L.E.A.P.S.(TM)**

L.E.A.P.S is a patented, T-cell modulation, peptide epitope delivery technology that enables CEL-SCI to design and synthesize proprietary peptide immunogens. L.E.A.P.S. compounds consist of a small T-cell binding peptide ligand linked with a disease-associated peptide antigen.

This new technology has been shown the potential in several animal models to preferentially direct immune response to a cellular (e.g., T-cell), humoral (antibody) or mixed pathway. Diseases for which antigenic epitope sequences have been identified, such as some infectious diseases, cancer, autoimmune diseases, allergic asthma and allergy, and select CNS diseases (e.g., Alzheimer's) may be potential candidates for development using this technology platform.  More...

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or by any other regulatory agency. Similarly, its safety of efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products

Partnering Philosophy & Corporate Partners

CEL-SCI's partnering philosophy is guided by the belief that any partnership entered into should serve the best interests of: 

  1. The patients who are/will be treated,
    The scientific, clinical, and commercial development of the medicine and
    CEL-SCI's shareholders.

CEL-SCI is open to any reasonable partnership proposals that will accelerate its being able to bring its medicines to market.

Multikine® (Leukocyte Interleukin, Injection):

Multikine (Leukocyte Interleukin, Injection) is the full name of this investigational therapy, which, for simplicity, is referred to in the remainder of this page as Multikine*.

CEL-SCI has a unique expertise in the development and manufacture of complex biologics. CEL-SCI is not a company that markets and sells drug products at the current time. Regardless, CEL-SCI believes it will be capable of marketing and selling Multikine on its own for head and neck cancer in both the United States and Europe if and once it is approved by the FDA (or EU regulators). Since its primary target is head & neck cancer surgeons, a rather small audience, CEL-SCI does not believe that a large sales force will be needed to commercialize Multikine, if and once it is approved by the FDA (or EU regulators) following the review of the total Multikine Biologics License Application.

Current Corporate Partners:

  1. Byron Biopharma
     
      a. Agreement Signed March 2009  
      b. Territory - Republic of South Africa  
      c. Revenue Share  

    Teva Pharmaceuticals Industries Ltd.
     
      a. Agreement Signed August 2008  
      b. Territory - Israel, Turkey, expanded to also cover Serbia and Croatia in August 2011.  
      c. Revenue Share  
      d. Website - http://www.tevapharm.com/  

     
    Orient Europharma Co. Ltd.
     
      a. Agreement Signed November 2000  
      b. Territory - Taiwan, Singapore, Hong Kong, Malaysia, expanded to also cover South Korea, the Philippines, Australia and New Zealand in the Fall of 2008.  
      c. Revenue Share  
      d. Website - http://www.oep.com.tw/  

     
    IDC-GP Pharm LLC 
     
      a. Agreement signed August 2011  
      b. Territory - Argentina and Venezuela  
      c. Revenue Share  
      d. Website - http://www.gp-pharm.com/  

     

Other Partnering Possibilities:

Based on the Company's L.E.A.P.S.TM** technology, as long as a disease epitope is available, CEL-SCI may be able to develop an effective treatment/vaccine using the L.E.A.P.S. technology.  The two leading candidates derived from this technology are the H1N1 treatment being developed as a possible treatment option for hospitalized patients and the Rheumatoid Arthritis treatment vaccine currently being tested in animal models of the disease.

 

* Multikine is the trademark that CEL-SCI has registered for this investigational therapy, and this proprietary name is subject to FDA review in connection with our future anticipated regulatory submission for approval. Multikine has not been licensed or approved for sale, barter or exchange by the FDA or any other regulatory agency. Similarly, its safety or efficacy has not been established for any use. Moreover, no definitive conclusions can be drawn from the early-phase, clinical-trials data summarized on this page or elsewhere on this website involving the investigational therapy Multikine (Leukocyte Interleukin, Injection). Further research is required, and early-phase clinical trial results must be confirmed in the well-controlled, Phase III clinical trial of this investigational therapy that is currently in progress.

** L.E.A.P.S. is the trademark of CEL-SCI for this investigational platform technology, and this proprietary name is subject to FDA review. No L.E.A.P.S. product has been approved for sale, barter or exchange by the FDA or any other regulatory agency for any use to treat disease in animals or humans. The safety or efficacy of these products has not been established for any use. Lastly, no definitive conclusions can be drawn from these early-phase, preclinical-trials data involving these investigational products.




http://stockcharts.com/freecharts/gallery.html?CVM

http://finance.yahoo.com/q?s=cvm&ql=1

http://stockcharts.com/h-sc/ui?s=CVM&p=D&yr=3&mn=0&dy=0&id=p60195179833

 

SureTrader
Interactive Brokers Advertisement
CVM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
CVM News: CEL-SCI Granted European Patent for Multikine’s Mechanism of Action in Making Tumors ‘Visible’ to the Immune System 10/10/2017 08:30:00 AM
CVM News: Current Report Filing (8-k) 10/06/2017 06:02:31 AM
CVM News: CEL-SCI Announces Update on Ongoing Arbitration against Former Clinical Research Organization 10/05/2017 09:45:00 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 10:32:11 AM
CVM News: Statement of Changes in Beneficial Ownership (4) 10/02/2017 10:09:58 AM
PostSubject
#12120  Sticky Note CEL-SCI Granted European Patent for Multikine’s Mechanism of trickledownfacists 10/10/17 08:40:02 AM
#7838  Sticky Note $CVM recent news/filings mick 01/18/16 02:09:58 PM
#5747  Sticky Note They keep coming!! Foxwoods Man 04/02/14 08:51:19 AM
#12152   IR said what? yankeesnyc27 10/17/17 02:19:16 AM
#12151   THis is the same management that thought that warfaretrader 10/16/17 05:28:13 PM
#12150   From a different board.... "spoke with IR, attorneys feel trickledownfacists 10/16/17 04:50:40 PM
#12149   Looks like the insurance company is getting left trickledownfacists 10/13/17 02:25:10 PM
#12148   Here you go. sinity 10/13/17 01:08:52 PM
#12147   Did the motion submitted by Inventiv lawyers intend rwa3848 10/13/17 12:01:13 PM
#12146   Fantastic trickledownfacists 10/13/17 09:07:44 AM
#12145   New ruling in Navigators v Pharmanet case: Trustbaby 10/13/17 08:51:34 AM
#12144   Very true L/C warfaretrader 10/12/17 08:12:27 AM
#12142   You do realize: it's not where you start; learning curve 10/12/17 03:20:50 AM
#12141   I think it's funny the 2 of you learning curve 10/12/17 03:14:46 AM
#12140   So, you think the patent was manipulation? For learning curve 10/12/17 03:09:46 AM
#12139   Come on boneheads.... non registered securities. Take a learning curve 10/12/17 02:57:49 AM
#12138   A suggestion,request,CHALLENGE ! yankeesnyc27 10/12/17 02:25:21 AM
#12137   Foxwood Not lame it's reality. Look historically sea alice 10/11/17 10:45:32 PM
#12136   People should feel free to express their positive Trustbaby 10/11/17 05:15:25 PM
#12135   Couldn't have said it better Fox! Guess warfaretrader 10/11/17 04:02:21 PM
#12134   I love when someone expresses issues with their Foxwoods Man 10/11/17 03:46:16 PM
#12133   Yes Sea, doom and gloom from my short warfaretrader 10/11/17 02:45:42 PM
#12132   Warfaretrader Doom and gloom from a short position. sea alice 10/11/17 02:09:47 PM
#12131   Black Candles have been a death sign for warfaretrader 10/11/17 11:05:26 AM
#12130   a few little shorts hitting the ask with cash_cow1 10/10/17 05:36:19 PM
#12129   I think next time I'am going to keep cash_cow1 10/10/17 04:41:36 PM
#12128   @yankee, I don't have a private message line cash_cow1 10/10/17 04:38:53 PM
#12127   cow? or BULL? yankeesnyc27 10/10/17 04:22:58 PM
#12126   http://www.wallstreetnews24.com/2017/10/10/early-moves-to-watch-cel-sci-corporat sinity 10/10/17 04:19:31 PM
#12124   Had that thought as well. trickledownfacists 10/10/17 10:41:51 AM
#12123   With CVM's history of Black Candles this needs warfaretrader 10/10/17 10:39:14 AM
#12122   https://seekingalpha.com/news/3300135-cel-sci-nabs-european-patent-covering-mult trickledownfacists 10/10/17 09:13:41 AM
#12121   Glad I pick Cel-Sci up yesterday for 1.80 cash_cow1 10/10/17 08:58:57 AM
#12120   CEL-SCI Granted European Patent for Multikine’s Mechanism of trickledownfacists 10/10/17 08:40:02 AM
#12119   https://www.biopharma-reporter.com/Article/2017/10/09/Cel-Sci-says-arbitration-w trickledownfacists 10/09/17 12:15:09 PM
#12118   https://www.stockscores.com/charts/charts/?ticker=CVM mick 10/08/17 12:45:24 PM
#12117   Well can be expected after being a shareholder steve2150 10/05/17 04:20:26 PM
#12116   Affirm trickledownfacists 10/05/17 02:23:46 PM
#12115   Correct - other than underwriting the costs of drkazmd65 10/05/17 02:20:22 PM
#12114   Lake Whillans had nothing to do with the trickledownfacists 10/05/17 02:03:42 PM
#12113   Same ole boring short shtick, stevo Trustbaby 10/05/17 01:59:08 PM
#12112   I hope I am wrong with this agreement. steve2150 10/05/17 01:50:33 PM
#12111   Affirm. With orphan drug status we have trickledownfacists 10/05/17 12:10:30 PM
#12110   Indeed it is possible - I'm just thinking drkazmd65 10/05/17 12:04:27 PM
#12109   It is also possible for them to win trickledownfacists 10/05/17 11:47:20 AM
#12108   If they win ~$40 MM, then they get drkazmd65 10/05/17 11:36:08 AM
#12107   Yes trickledownfacists 10/05/17 11:27:54 AM
#12106   I think so trickledownfacists 10/05/17 11:27:39 AM
#12105   If they win $40M, then what? Does ducruacuteo11 10/05/17 11:25:00 AM
#12104   At the very least - both the law drkazmd65 10/05/17 11:24:58 AM
#12103   And that it looks like they will win trickledownfacists 10/05/17 11:05:04 AM
#12102   The part I am most interested in is drkazmd65 10/05/17 10:49:02 AM
#12101   CEL-SCI Announces Update on Ongoing Arbitration against Former trickledownfacists 10/05/17 10:00:06 AM
PostSubject